Myasthenic crisis in the puerperium: the possible importance of α‐fetoprotein. Case report

  title={Myasthenic crisis in the puerperium: the possible importance of $\alpha$‐fetoprotein. Case report},
  author={Yasuyuki Hatada and Masahide Munemura and I. Matsuo and Shunichi Fujisaki and Hitoshi Okamura and N Yamanaka},
  journal={BJOG: An International Journal of Obstetrics \& Gynaecology},
The patient was a 27-ycar-old in her first pregnancy with mild systemic myasthenia gravis (Osserman classification IIA), with weakness, ptosis and diplopia since the age of 24. There was no significant gynaecological history. She was admitted at 37 weeks gestation for observation but had been in remission from 20 weeks, and had no exacerbation before delivery. In addition to anti-acetylcholine receptor (anti-AChR) antibody, she was also found to have antinuclear antibodies. The assessment of… 
Myasthenia gravis complicating pregnancy
  • R. Khanna, A. Kriplani, K. Buckshee
  • Medicine
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 1994
Myasthenic crisis: report of 24 cases.
It is concluded that in spite of all the therapeutics options, there were non statistically significant differences in the outcome of patients that underwent thymectomy and those who did not.
Increased risk for clinical onset of myasthenia gravis during the postpartum period
The postpartum period was confirmed to be significantly associated with the onset of symptoms of MG in Norwegian women with MG (relative risk 5.5, 95% confidence interval 2.6–11.6).
Successful management of pregnancy‐aggravated myasthenic crisis after complete remission of the disease
This case highlights that early recognition of the condition and intensive care of the patient can improve the outcome in patients with myasthenia gravis.
Myasthenia gravis and pregnancy.
Miastenia Gravis (M.G.)
Se hace una revision que comprende la epidemiologia, inmunopatologia, clasificacion, manifestaciones clinicas, diagnostico y diferentes modalidades terapeuticas de la Miastenia Gravis
Peripheral nerve and neuromuscular disorders.


The study indicates a strong relationship between clinical course and AChR-ab in the individual patient when sustained improvement over 12 months and A chiral receptor antibody decreases greater than 50% are examined.
Inhibitory effect of alpha-fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor.
The binding of myasthenia gravis antibody acetylcholine receptor (AcChoR) as measured in vitro by Radioimmunoassay with 125I-labeled alpha-bungarotoxin (alpha-BuTx) suggests a similar effect in vivo in pregnant women with myast Hennessy gravis.
Antibody to acetylcholine receptor in myasthenia gravis
Assay of antireceptor antibody should prove a useful test in the diagnosis of myasthenia gravis, and presence or titer of antibody did not appear to correlate with age, sex, steroid therapy, or duration of symptoms.
No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis
Serum acetylcholine receptor antibodies were measured serially in myasthenia gravis patients before and after early extended thymectomy; they received no medication postoperatively. Clinical
Acetylcholine receptor antibody in the diagnosis of myasthenia gravis
The role of AchR antibody assay in the diagnosis of ocular and generalized myasthenia gravis is reviewed, and compared to standard means of diagnosing the disease by clinical and electrophysiological methods.
Myasthenia Gravis
Prevalence, clinical correlates, and diagnostic value
  • Neurology